Iron isomaltoside 1000

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Iron isomaltoside 1000
Accession Number
DB12208
Type
Small Molecule
Groups
Approved, Investigational
Description

Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

Synonyms
  • Monofer
Categories
UNII
3M6325NY1R
CAS number
1370654-58-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3-Aza-2,3-Dihydrogeranyl DiphosphateIron isomaltoside 1000 can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidIron isomaltoside 1000 can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
AloglutamolAloglutamol can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911299

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableChronic Kidney Disease (CKD)1
1CompletedBasic SciencePatients With Chemotherapy Induced Anemia (CIA)1
1CompletedTreatmentAnemias / Deficiency Diseases / Hematologic Diseases / Iron Deficiency Anemia (IDA) / Iron Metabolism Disorders1
1CompletedTreatmentInflammatory Bowel Diseases (IBD)1
1CompletedTreatmentNon-dialysis Dependent Chronic Kidney Disease1
1CompletedTreatmentNon-hematological Malignancies1
2WithdrawnTreatmentRestless Legs Syndrome (RLS)1
2, 3RecruitingTreatmentHeart Transplant Recipients1
3CompletedNot AvailableInflammatory Bowel Diseases (IBD)1
3CompletedTreatmentAnemias / Inflammatory Bowel Diseases (IBD)1
3CompletedTreatmentChemotherapy Induced Anemia / Non-Myeloid Malignancies1
3CompletedTreatmentChronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA)1
3CompletedTreatmentChronic Kidney Disease (CKD) / Iron-Deficiency Anemias1
3CompletedTreatmentChronic Kidney Disease Stage 5 (Dialysis Dependent)1
3CompletedTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentIDA - Iron Deficiency Anemia2
3CompletedTreatmentInflammatory Bowel Diseases (IBD)1
3CompletedTreatmentIron Deficiency Anemia (IDA)3
3CompletedTreatmentIron-Deficiency1
3CompletedTreatmentIron-Deficiency Anemias1
3CompletedTreatmentNon-anaemic Patients Undergoing Cardiac Surgery1
3CompletedTreatmentPostpartum Haemorrhage (PPH)1
3CompletedTreatmentSevere Postpartum Haemorrhage1
3RecruitingTreatmentAnemias / Hip Fracture Pathologic / Hip Fractures Pathologic1
3RecruitingTreatmentColorectal Cancers / Iron-Deficiency Anemias1
3WithdrawnTreatmentIron Deficiency Anemia (IDA)1
4Active Not RecruitingTreatmentIron-Deficiency Anemias1
4Enrolling by InvitationTreatmentPost Gastrectomy Anemia1
4RecruitingTreatmentAnemias / Esophageal Cancers / Malignant Neoplasm of Stomach1
4RecruitingTreatmentHeart Failure / Iron Deficiency / Left Ventricular Systolic Dysfunction1
4RecruitingTreatmentInflammatory Bowel Diseases (IBD)1
4RecruitingTreatmentIntravenous Drug Usage / Iron-Deficiency Anemias / Neoplasms, Colorectal / Surgery, Colorectal1
4RecruitingTreatmentIron Deficiency Anemia of Pregnancy1
Not AvailableCompletedNot AvailableAnaemia in Chronic Kidney Disease1
Not AvailableCompletedNot AvailableIron Deficiency Anemia (IDA)2
Not AvailableCompletedPreventionAnemias / Knee Arthropathy1
Not AvailableCompletedPreventionPostpartum Anemia1
Not AvailableNot Yet RecruitingTreatmentIron-Deficiency1
Not AvailableRecruitingNot AvailableAnemias / Arthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee1
Not AvailableRecruitingNot AvailableAnemias / Iron Deficiency Anemia (IDA)1
Not AvailableRecruitingPreventionFacial Asymmetry / Prognathism / Retrognathism1
Not AvailableRecruitingTreatmentComplex Valvular Heart Surgery1
Not AvailableRecruitingTreatmentIron Deficiency Anemia Treatment1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 20, 2016 15:36 / Updated on June 04, 2019 07:34